About Mitogen-activated protein kinase 13
Mitogen-activated protein kinase 13 (MAPK13) is a protein
from Homo sapiens identified by UniProt accession
O15264, 365 residues long.
MolForge cross-references it against 0 known binders and
144 disease associations.
Target properties
| Protein name | Mitogen-activated protein kinase 13 |
| UniProt accession | O15264 |
| Gene | MAPK13 |
| Organism | Homo sapiens |
| Length | 365 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (144)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.29
- blood protein measurement · score 0.28
- neurodegenerative disease · score 0.26
- glioblastoma multiforme · score 0.25
- breast adenocarcinoma · score 0.25
- cutaneous melanoma · score 0.23
- neuroinflammatory disorder · score 0.23
- attention deficit hyperactivity disorder · score 0.12
- antisocial behaviour measurement · score 0.12
- substance abuse · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15264-F1 | alphafold | PREDICTED | 89.05 | — |
Amino-acid sequence (365 residues)
MSLIRKKGFY KQDVNKTAWE LPKTYVSPTH VGSGAYGSVC SAIDKRSGEK VAIKKLSRPF QSEIFAKRAY RELLLLKHMQ HENVIGLLDV FTPASSLRNF YDFYLVMPFM QTDLQKIMGM EFSEEKIQYL VYQMLKGLKY IHSAGVVHRD LKPGNLAVNE DCELKILDFG LARHADAEMT GYVVTRWYRA PEVILSWMHY NQTVDIWSVG CIMAEMLTGK TLFKGKDYLD QLTQILKVTG VPGTEFVQKL NDKAAKSYIQ SLPQTPRKDF TQLFPRASPQ AADLLEKMLE LDVDKRLTAA QALTHPFFEP FRDPEEETEA QQPFDDSLEH EKLTVDEWKQ HIYKEIVNFS PIARKDSRRR SGMKL
Explore Mitogen-activated protein kinase 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets